(DHI) DR Horton - Overview
Sector: Consumer Cyclical | Industry: Residential Construction | Exchange: NYSE (USA) | Market Cap: 40.759m USD | Total Return: 19.7% in 12m
Avg Turnover: 324M
EPS Trend: -83.0%
Qual. Beats: 0
Rev. Trend: -57.1%
Qual. Beats: 0
Warnings
Choppy Below Avwap Earnings
Tailwinds
Confidence
D.R. Horton, Inc. (DHI) is the largest homebuilder by volume in the United States, operating across 126 markets in 36 states. The company’s business model is vertically integrated, encompassing land acquisition, residential construction, and the sale of single-family detached and attached homes. Beyond construction, the firm provides ancillary financial services including mortgage financing, title insurance, and property insurance to its customer base.
The company maintains a diversified portfolio that includes multi-family and single-family rental properties, alongside strategic holdings in water rights and non-residential real estate. In the homebuilding sector, large-scale players like D.R. Horton often utilize an asset-light strategy by securing land through option contracts to mitigate capital risk during market fluctuations. Performance in this industry is highly sensitive to national mortgage rates and regional housing inventory levels.
Investors can further examine these sector dynamics and historical valuation trends on ValueRay. Founded in 1978 and headquartered in Arlington, Texas, D.R. Horton focuses on serving a broad range of homebuyers through multiple brands tailored to different price points and geographic regions.
- High mortgage rates and limited resale inventory drive demand for new construction
- Strategic use of mortgage rate buy-downs maintains sales volume and buyer affordability
- Expansion of rental property segment diversifies revenue beyond traditional single-family home sales
- Regional land acquisition costs and labor shortages impact gross homebuilding margins
- Dominant market share in entry-level housing targets resilient first-time homebuyer demographic
| Net Income: 3.17b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.19 > 1.0 |
| NWC/Revenue: 84.43% < 20% (prev 91.75%; Δ -7.32% < -1%) |
| CFO/TA 0.10 > 3% & CFO 3.65b > Net Income 3.17b |
| Net Debt (4.72b) to EBITDA (4.13b): 1.14 < 3 |
| Current Ratio: 6.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (289.0m) vs 12m ago -7.96% < -2% |
| Gross Margin: 22.80% > 18% (prev 0.26%; Δ 2.25k% > 0.5%) |
| Asset Turnover: 93.60% > 50% (prev 98.95%; Δ -5.35% > 0%) |
| Interest Coverage Ratio: 44.09 > 6 (EBITDA TTM 4.13b / Interest Expense TTM 91.3m) |
| A: 0.79 (Total Current Assets 33.0b - Total Current Liabilities 4.80b) / Total Assets 35.6b |
| B: 0.90 (Retained Earnings 32.0b / Total Assets 35.6b) |
| C: 0.11 (EBIT TTM 4.03b / Avg Total Assets 35.6b) |
| D: 2.82 (Book Value of Equity 32.0b / Total Liabilities 11.4b) |
| Altman-Z'' = 11.85 = AAA |
| DSRI: 1.17 (Receivables 458.9m/415.5m, Revenue 33.3b/35.3b) |
| GMI: 1.12 (GM 22.80% / 25.50%) |
| AQI: 1.63 (AQ_t 0.06 / AQ_t-1 0.03) |
| SGI: 0.94 (Revenue 33.3b / 35.3b) |
| TATA: -0.01 (NI 3.17b - CFO 3.65b) / TA 35.6b) |
| Beneish M = -2.46 (Cap -4..+1) = BBB |
As of May 26, 2026, the stock is trading at USD 143.73 with a total of 1,811,300 shares traded.
Over the past week, the price has changed by +6.16%,
over one month by -9.52%,
over three months by -8.44% and
over the past year by +19.69%.
DR Horton has received a consensus analysts rating of 3.62. Therefore, it is recommended to hold DHI.
- StrongBuy: 6
- Buy: 3
- Hold: 10
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 165.3 | 15% |
P/E Trailing = 13.4958
P/E Forward = 13.8696
P/S = 1.2222
P/B = 1.7252
P/EG = 1.347
Revenue TTM = 33.3b USD
EBIT TTM = 4.03b USD
EBITDA TTM = 4.13b USD
Long Term Debt = 5.70b USD (from longTermDebt, last quarter)
Short Term Debt = 865.0m USD (from shortLongTermDebt, last quarter)
Debt = 6.63b USD (from shortLongTermDebtTotal, last quarter) + Leases 70.0m
Net Debt = 4.72b USD (calculated: Debt 6.63b - CCE 1.92b)
Enterprise Value = 45.5b USD (40.8b + Debt 6.63b - CCE 1.92b)
Interest Coverage Ratio = 44.09 (Ebit TTM 4.03b / Interest Expense TTM 91.3m)
EV/FCF = 13.00x (Enterprise Value 45.5b / FCF TTM 3.50b)
FCF Yield = 7.69% (FCF TTM 3.50b / Enterprise Value 45.5b)
FCF Margin = 10.49% (FCF TTM 3.50b / Revenue TTM 33.3b)
Net Margin = 9.51% (Net Income TTM 3.17b / Revenue TTM 33.3b)
Gross Margin = 22.80% ((Revenue TTM 33.3b - Cost of Revenue TTM 25.7b) / Revenue TTM)
Gross Margin QoQ = 22.54% (prev 23.16%)
Tobins Q-Ratio = 1.28 (Enterprise Value 45.5b / Total Assets 35.6b)
Interest Expense / Debt = 1.38% (Interest Expense 91.3m / Debt 6.63b)
Taxrate = 24.14% (209.4m / 867.4m)
NOPAT = 3.05b (EBIT 4.03b * (1 - 24.14%))
Current Ratio = 6.86 (Total Current Assets 33.0b / Total Current Liabilities 4.80b)
Debt / Equity = 0.28 (Debt 6.63b / totalStockholderEquity, last quarter 23.6b)
Debt / EBITDA = 1.14 (Net Debt 4.72b / EBITDA 4.13b)
Debt / FCF = 1.35 (Net Debt 4.72b / FCF TTM 3.50b)
Total Stockholder Equity = 24.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.90% (Net Income 3.17b / Total Assets 35.6b)
RoE = 13.24% (Net Income TTM 3.17b / Total Stockholder Equity 24.0b)
RoCE = 13.57% (EBIT 4.03b / Capital Employed (Equity 24.0b + L.T.Debt 5.70b))
RoIC = 8.59% (NOPAT 3.05b / Invested Capital 35.5b)
WACC = 7.27% (E(40.8b)/V(47.4b) * Re(8.28%) + D(6.63b)/V(47.4b) * Rd(1.38%) * (1-Tc(0.24)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -6.48%
[DCF] Terminal Value 77.97% ; FCFF base≈3.19b ; Y1≈3.66b ; Y5≈5.38b
[DCF] Fair Price = 269.0 (EV 81.0b - Net Debt 4.72b = Equity 76.3b / Shares 283.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -83.00 | EPS CAGR: -10.03% | SUE: 0.34 | # QB: 0
Revenue Correlation: -57.14 | Revenue CAGR: -2.43% | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.99 | Chg30d=+7.64% | Revisions=+6% | Analysts=13
EPS current Year (2026-09-30): EPS=10.58 | Chg30d=+2.47% | Revisions=+47% | GrowthEPS=-8.6% | GrowthRev=-1.1%
EPS next Year (2027-09-30): EPS=12.05 | Chg30d=+1.34% | Revisions=+0% | GrowthEPS=+13.9% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +47%